Exchange: NASDAQ·Updated 06:16 PM EDT
MAZE logo

MAZEMaze Therapeutics Inc.

$28.43
$1.41
(5.22%)
Today
Closed $28.43
$0.56
(1.97%)
After Hours
EarningsAug 12
Mkt Cap$1.57B
Vol3.55M
News
all
press releases
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...
Yahoo! Finance: News
News Placeholder
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts
Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider directly...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Here's Why
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy...
MarketBeat
News Placeholder
Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering
(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds...
Nasdaq News: Markets
News Placeholder
239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc
Mass General Brigham Inc acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's What Happened
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's Why...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.